Resultats de la cerca - Adewoye, Adeboye

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study per Kotasek, Dusan, Tebbutt, Niall, Desai, Jayesh, Welch, Stephen, Siu, Lillian L, McCoy, Sheryl, Sun, Yu-Nien, Johnson, Jessica, Adewoye, Adeboye H, Price, Timothy

Obtenir text complet Obtenir text complet Obtenir text complet

Sickle Cell Leg Ulcers: Associations with Haemolysis and SNPs in Klotho, TEK and Genes of the TGF-β/BMP Pathway: —Sickle Cell Leg Ulcers, Genetics and Haemolysis— per Nolan, Vikki G., Adewoye, Adeboye, Baldwin, Clinton, Wang, Ling, Ma, Qianli, Wyszynski, Diego F., Farrell, John J., Sebastiani, Paola, Farrer, Lindsay A., Steinberg, Martin H.

Obtenir text complet Obtenir text complet Obtenir text complet

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer per De Boer, Richard H., Kotasek, Dusan, White, Shane, Koczwara, Bogda, Mainwaring, Paul, Chan, Arlene, Melara, Rebeca, Ye, Yining, Adewoye, Adeboye H., Sikorski, Robert, Kaufman, Peter A.

Obtenir text complet Obtenir text complet Obtenir text complet

Sickle Cell Vaso-occlusive Crisis Induces the Release of Circulating Serum Heat Shock Protein-70 per Adewoye, Adeboye H., Klings, Elizabeth S., Farber, Harrison W., Palaima, Elizabeth, Bausero, Maria A., McMahon, Lillian, Odhiambo, Adam, Surinder, Safaya, Yoder, Mark, Steinberg, Martin H., Asea, Alexzander

Obtenir text complet Obtenir text complet Obtenir text complet

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies per Kater, Arnon P., Tonino, Sanne H., Spiering, Marjolein, Chamuleau, Martine E. D., Liu, Roberto, Adewoye, Adeboye Henry, Gao, Jie, Dreiling, Lyndah, Xin, Yan, Doorduijn, Jeanette K., Kersten, Marie José

Obtenir text complet Obtenir text complet Obtenir text complet

Evaluation of the CLL-IPI in Relapsed and Refractory Chronic Lymphocytic Leukemia in Idelalisib Phase 3 Trials per Soumerai, Jacob D., Ni, Ai, Xing, Guan, Huang, Julie, Furman, Richard R., Jones, Jeffrey, Sharman, Jeffrey P., Hallek, Michael, Adewoye, Adeboye H., Dubowy, Ronald, Dreiling, Lyndah, Zelenetz, Andrew D.

Obtenir text complet Obtenir text complet Obtenir text complet

A network model to predict the risk of death in sickle cell disease per Sebastiani, Paola, Nolan, Vikki G., Baldwin, Clinton T., Abad-Grau, Maria M., Wang, Ling, Adewoye, Adeboye H., McMahon, Lillian C., Farrer, Lindsay A., Taylor, James G., Kato, Gregory J., Gladwin, Mark T., Steinberg, Martin H.

Obtenir text complet Obtenir text complet Obtenir text complet

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Contro... per Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S., Robak, Tadeusz, Sharman, Jeff P., Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H., Dreiling, Lyndah K., Kim, Yeonhee, Stilgenbauer, Stephan, Hillmen, Peter

Obtenir text complet Obtenir text complet Obtenir text complet